Found Insurance vs Cash-Pay GLP-1: 2026 Plans and Costs Compared

Last reviewed: September 5, 2026 Last updated: September 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

Found operates two distinct pricing tracks: an insurance track (monthly $199, or $99/month effective when prepaid annually) that covers the care program and compounded medication but bills branded drugs separately, and a cash-pay track (monthly $289 semaglutide, $359 tirzepatide, with steep discounts for 12-month prepay). If your insurance covers GLP-1 drugs and you qualify for Found's in-network clinicians—serving approximately one in three Americans—the insurance track delivers the lowest total cost. If you pay cash or your insurer excludes weight management, Found's 12-month prepaid semaglutide plan ($2,028 upfront, effective $169/month) undercuts its own month-to-month rate by $1,729 over twelve months, though PlexusDx's six-month semaglutide rate ($149/month, $1,788 over twelve months) sits between Found's annual and monthly tiers without requiring a full-year commitment. The decision hinges on your insurance status, liquidity for prepayment, and whether you want integrated app-based support or a streamlined clinical model.

At-a-glance comparison: Found insurance vs Found cash-pay vs PlexusDx

Sources: Found public pricing pages and PlexusDx product pages, both captured September 4, 2026. Prepaid per-month equivalents and 12-month totals are our calculations.

Normalized 12-month cost: insurance track vs cash-pay track vs PlexusDx

Found insurance track (compounded semaglutide)

• Monthly plan: $199/month × 12 = $2,388 over twelve months, plus copays (~$30/visit typical).
• Annual prepaid plan: $1,188 upfront = $1,188 over twelve months (effective $99/month), plus copays.
• Prepay savings: $2,388 − $1,188 = $1,200 (before copays).

The insurance track assumes your insurer covers GLP-1 for weight management and Found's clinicians are in-network. Found reports in-network status for approximately one in three Americans (captured September 4, 2026). Branded medications—Ozempic, Wegovy, Zepbound, Mounjaro, Saxenda, Victoza, Foundayo (orforglipron), and Rybelsus—are available but billed separately; the $199 or $99/month fee covers only the care program and compounded drugs.

Found cash-pay track (compounded semaglutide)

• Monthly plan: $289/month, billed every 4 weeks = 13 charges/year = $3,757 over twelve months.
• 12-month prepaid plan: $2,028 upfront = $2,028 over twelve months (effective $169/month).
• Prepay savings: $3,757 − $2,028 = $1,729.

The cash-pay track bundles care program and compounded medication; branded drugs remain available but billed separately. The 12-month prepay discount is the steepest Found offers, but it requires full payment upfront with no monthly option to step down mid-year.

Found cash-pay track (compounded tirzepatide)

• Monthly plan: $359/month × 13 (every 4 weeks) = $4,667 over twelve months.
• 12-month prepaid plan: effective $239/month = $2,868 over twelve months (our calculation from the effective rate).
• Prepay savings: $4,667 − $2,868 = $1,799.

PlexusDx (compounded semaglutide injection)

• Month-to-month: $189/month × 12 = $2,268 over twelve months.
• 6-month subscription: $149/month × 12 = $1,788 over twelve months.
• No membership fee, no hidden charges: the monthly rate covers prescription, medication, provider visit, and shipping.

PlexusDx (compounded tirzepatide injection)

• Month-to-month: $289/month × 12 = $3,468 over twelve months.
• 6-month subscription: $249/month × 12 = $2,988 over twelve months.

All figures above are our calculations from publicly posted rates. Found's every-4-weeks billing produces 13 charges per calendar year; PlexusDx bills calendar monthly (12 charges). Found requires annual prepayment upfront to unlock its lowest effective rates; PlexusDx's six-month subscriptions bill every six months, so two payments over twelve months.

When Found's insurance track wins

If your health plan covers GLP-1 drugs for weight management and Found's clinicians are in-network for your insurer, the annual insurance prepay ($1,188 upfront, effective $99/month) delivers the lowest total program cost in this comparison—even after adding typical copays (~$30/visit). The insurance track provides access to branded medications (Ozempic, Wegovy, Zepbound, Mounjaro, Saxenda, Victoza, Foundayo, Rybelsus) billed separately through your insurer, alongside compounded options included in the program fee. Found reports in-network status for approximately one in three Americans (captured September 4, 2026), so verification at intake is essential. The monthly insurance option ($199/month) offers flexibility if you're unsure about a year-long commitment, though the prepay discount saves $1,200 over twelve months before copays.

When Found's cash-pay track wins

If you pay out-of-pocket and want an app-driven program with 24/7 care team access, behavioral coaching, and an AI concierge (Aimee), Found's 12-month cash-pay prepay for semaglutide ($2,028 upfront, effective $169/month) costs $240 less over twelve months than PlexusDx's six-month rate ($1,788). For tirzepatide, Found's 12-month prepay (effective $239/month, $2,868 over twelve months) sits $120 below PlexusDx's six-month rate ($2,988). The trade-off is liquidity: Found requires the full year paid upfront with no mid-year step-down, whereas PlexusDx bills every six months. Found's monthly cash-pay rates ($289 semaglutide, $359 tirzepatide) are materially higher than PlexusDx month-to-month ($189 semaglutide, $289 tirzepatide), making them appropriate only for short trials or when prepayment isn't feasible.

When PlexusDx fits

PlexusDx eliminates membership fees, program charges, and app subscriptions: the monthly medication rate covers prescription, compounded drug, provider visit, and shipping in one transparent line item. The six-month semaglutide subscription ($149/month, $1,788 over twelve months) sits between Found's annual prepay ($2,028) and monthly cash rate ($3,757), requiring half the upfront commitment. PlexusDx month-to-month semaglutide ($189) undercuts Found's monthly cash-pay ($289) by $100/month with no contract, making it the lowest-friction option for those testing tolerance or uncertain about duration. For tirzepatide, PlexusDx month-to-month ($289) matches Found's cash monthly ($359) by a $70 margin, and the six-month rate ($249) delivers $2,988 over twelve months against Found's $2,868 annual prepay—a $120 difference for six months' additional flexibility. PlexusDx does not offer branded medications, insurance billing, or behavioral app features; the model prioritizes clinical essentials and cost transparency over integrated lifestyle coaching.

What's included: Found insurance vs cash-pay

Both Found tracks include access to board-certified clinicians, the Found app, 24/7 care team support, personalized care plans incorporating GLP-1s, healthy-habits guidance, and Aimee—Found's AI weight-loss and lifestyle concierge (captured September 4, 2026). The insurance track bundles compounded medications in the program fee ($199 monthly or $99 effective annual); branded medications are available but billed separately through your insurer, and visits may require copays (typically ~$30 for most Found members, per Found's disclosure). The cash-pay track bundles compounded medications in the program fee ($289 semaglutide, $359 tirzepatide monthly, or lower on prepaid plans); branded medications are similarly available but billed separately as a cash transaction. Both tracks are HSA/FSA eligible. Found grants a full refund if you're not clinically eligible, and you can cancel anytime in the app (captured July 20, 2026).

Billing cadence and prepayment mechanics

Found's monthly plans bill every four weeks, producing 13 charges per calendar year rather than 12. The 12-month cash-pay plans require payment upfront—$2,028 for semaglutide, calculated effective $169/month; tirzepatide effective $239/month (captured July 20, 2026). The annual insurance plan requires $1,188 upfront, effective $99/month. Found's three-month and six-month cash-pay options (semaglutide $249 and $219/month effective; tirzepatide $309 and $289/month effective) bill every 12 or 24 weeks respectively, also requiring lump-sum payment at each renewal (captured July 20, 2026). PlexusDx bills calendar monthly for month-to-month subscriptions and every six months for six-month subscriptions—two payments over twelve months rather than one upfront charge. This difference in cadence affects cash flow: Found's annual plans lock in the lowest rate but demand the full commitment upfront, while PlexusDx's six-month model spreads liquidity across two billing events.

Insurance verification and coverage

Found states its clinicians are in-network "for 1 in 3 Americans" (captured September 4, 2026). Whether your specific plan covers GLP-1 drugs for weight management—and whether Found's clinicians hold in-network status with your insurer—requires intake verification. Found's insurance pricing ($199 monthly, $99 effective annual) covers the care program and compounded medications; branded drugs (Ozempic, Wegovy, Zepbound, Mounjaro, Saxenda, Victoza, Foundayo, Rybelsus) are prescribed when clinically appropriate but billed separately, with cost determined by your insurance formulary, copay structure, and prior-authorization requirements. If your insurer excludes weight management or requires a formulary step-edit Found cannot satisfy, you default to the cash-pay track. PlexusDx does not bill insurance and does not offer branded medications; all pricing is transparent cash-pay for compounded drugs only.

Medication availability

Found offers compounded semaglutide injection and compounded tirzepatide injection on both insurance and cash-pay tracks. Branded options—Ozempic, Wegovy, Zepbound, Mounjaro, Saxenda, Victoza, Foundayo (orforglipron), and Rybelsus—are available when clinically appropriate but billed separately (captured September 4, 2026). PlexusDx offers compounded semaglutide injection (month-to-month $189, six-month $149) and compounded tirzepatide injection (month-to-month $289, six-month $249), alongside oral semaglutide capsules (month-to-month $289, six-month $249), oral tirzepatide capsules (month-to-month $349, six-month $279), and a microdose GLP-1 protocol ($129 month-to-month). PlexusDx does not prescribe or dispense branded medications.

Evidence gaps and uncertainty

Found's pricing is checkout-verified for its insurance and cash-pay tracks (captured September 4, 2026 and July 20, 2026). We verified program fees, billing cadences, prepaid totals, and inclusion statements directly from Found's public pricing pages and checkout flows. One minor uncertainty: the "typical copay about $30" figure for insurance-track visits is Found's reported average, not a guarantee; actual copays depend on your plan's design. Found's refund policy ("full refund if you're not clinically eligible") and cancellation terms ("cancel anytime in its app") are stated on Found's site but were not tested through actual cancellation. All 12-month cost totals, prepaid per-month equivalents, and savings figures in this article are our calculations from the published rates and billing cadences.

Methodology and freshness

We captured Found's public pricing pages on September 4, 2026, and cross-referenced earlier captures from July 20, 2026. We recorded program fees, medication costs, billing cadences, prepaid discounts, insurance-track terms, copay language, included services, branded-medication availability, refund and cancellation policies, and in-network coverage statements. We calculated 12-month totals by multiplying monthly rates by the number of billing events per year (13 for Found's every-4-weeks cadence, 12 for calendar-monthly plans). Prepaid per-month equivalents divide the upfront charge by the commitment length in months. PlexusDx pricing is drawn from live product pages (semaglutide-injection, tirzepatide-injection) captured September 5, 2026. No provider in this comparison guarantees eligibility, medication selection, dose, or clinical outcomes; a licensed clinician reviews your intake and determines whether a prescription is appropriate. We did not submit payment to any competitor or test cancellation/refund flows firsthand.

Frequently Asked Questions

Does Found's insurance track cover the medication itself, or only the program?

Found's insurance track fee ($199 monthly or $99/month effective annual) covers the care program and compounded medications. Branded GLP-1 drugs—Ozempic, Wegovy, Zepbound, Mounjaro, Saxenda, Victoza, Foundayo, Rybelsus—are available but billed separately through your insurance; the program fee does not include their cost. Visits may require copays, typically around $30 for most Found members, per Found's disclosure captured September 4, 2026.

How does Found's every-4-weeks billing affect my annual cost?

Billing every four weeks produces 13 charges per calendar year instead of 12. Found's monthly cash-pay semaglutide rate of $289 becomes $3,757 over twelve months (13 × $289), not $3,468. This cadence applies to all Found monthly plans—insurance and cash-pay—so comparing annual totals requires multiplying the stated monthly rate by 13, not 12, unless you choose a prepaid option that bills once upfront.

Can I switch from Found's monthly plan to the annual prepaid plan mid-year?

Found's public pricing pages (captured September 4, 2026) do not specify mid-contract plan changes. The annual prepaid rates require upfront payment at enrollment; whether Found allows a mid-year switch from monthly to prepaid, and whether any partial credit applies, should be confirmed with Found's support team before committing to the monthly option if you're considering a later upgrade.

Is PlexusDx's six-month rate truly cheaper than Found's 12-month prepay for semaglutide?

No. Found's 12-month cash-pay semaglutide prepay costs $2,028 over twelve months; PlexusDx's six-month semaglutide rate ($149/month) costs $1,788 over twelve months. PlexusDx is $240 less expensive, but requires only half the upfront commitment (two six-month payments of $894 each, rather than one $2,028 charge). Found wins on absolute lowest cost if you can prepay the full year; PlexusDx wins on liquidity and flexibility.

Does Found require me to stay on a compounded drug if my insurance covers branded Wegovy or Zepbound?

No. Found offers both compounded and branded GLP-1 medications; a clinician determines which is clinically appropriate. On the insurance track, branded drugs are billed separately through your insurer, so formulary, prior authorization, and copay rules apply. On the cash-pay track, branded drugs are also available but billed separately as a cash charge. The program fee on either track covers only compounded medications; branded drugs are an additional line item regardless of which track you choose.

Sources

• Found public pricing pages: insurance and cash-pay rates, medication options, billing cadence, included services, refund and cancellation terms (captured September 4, 2026 and July 20, 2026)
• PlexusDx product pages: semaglutide-injection and tirzepatide-injection pricing, subscription terms (captured September 5, 2026)
• PlexusDx internal comparison grid: competitor verification status and evidence classification (captured July 17–23, 2026)

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.